1. Home
  2. PGY vs DNTH Comparison

PGY vs DNTH Comparison

Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$18.47

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$92.84

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
DNTH
Founded
2016
2015
Country
United States
United States
Employees
493
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
5.9B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
PGY
DNTH
Price
$18.47
$92.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$34.50
$121.00
AVG Volume (30 Days)
1.9M
593.4K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
116.43
N/A
EPS
0.77
N/A
Revenue
$1,301,360,000.00
$2,036,000.00
Revenue This Year
$14.27
N/A
Revenue Next Year
$14.39
$29.48
P/E Ratio
$26.97
N/A
Revenue Growth
26.07
N/A
52 Week Low
$10.40
$32.28
52 Week High
$35.55
$117.88

Technical Indicators

Market Signals
Indicator
PGY
DNTH
Relative Strength Index (RSI) 47.05 N/A
Support Level $20.34 N/A
Resistance Level $23.45 N/A
Average True Range (ATR) 0.99 0.00
MACD -0.21 0.00
Stochastic Oscillator 21.30 0.00

Price Performance

Historical Comparison
PGY
DNTH

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: